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Most cultured cell types secrete small latent trans-
forming growth factor-b (TGF-b) as a disulfide-bonded
complex with a member of the latent TGF-b binding
protein (LTBP) family. Using the baculovirus expression
system, we have mapped the domain of LTBP-1 mediat-
ing covalent association with small latent TGF-b1. Coex-
pression in Sf9 cells of small latent TGF-b1 with deletion
mutants of LTBP-1 showed that the third eight-cysteine
repeat of LTBP-1 is necessary and sufficient for covalent
interaction with small latent TGF-b1. Analysis by mass
spectrometry of this eight-cysteine repeat, produced as
a recombinant peptide in Sf9 cells, confirmed that it was
N-glycosylated, as expected from the primary sequence.
No other post-translational modifications of this domain
were detected. Alkylation of the recombinant peptide
with vinyl pyridine failed to reveal any free cysteines,
indicating that, in the absence of small latent TGF-b, the
eight cysteines of this domain are engaged in intramo-
lecular bonds. These data demonstrate that the third
LTBP-1 eight-cysteine repeat recognizes and associates
covalently with small latent TGF-b1 through a mecha-
nism that does not require any specific post-transla-
tional modification of this domain. They also suggest
that this domain adopts different conformations de-
pending on whether it is free or bound to small latent
TGF-b.
First identified as a transforming agent on cultured fibro-
blasts, transforming growth factor-b (TGF-b)1 is a potent, ubiq-
uitous regulator of cell growth and differentiation and a mod-
ulator of the immune system (1–3). TGF-b also stimulates
extracellular matrix production both by increasing the rate of
synthesis of extracellular matrix components like fibronectin,
collagen I, and biglycan, and by down-regulating the overall
proteolytic activity. Three isoforms of TGF-b, TGF-b1, TGF-b2,
and TGF-b3, have been identified in mammals. These isoforms
have similar, but distinct, activities and are differently distrib-
uted among tissues. Translation of TGF-b mRNA results in the
formation of a 105-kDa dimeric proform, which is proteolyti-
cally cleaved in the Golgi apparatus to mature TGF-b (4). Upon
secretion, the mature growth factor (m 5 25 kDa), remains
noncovalently associated with the propeptide (also known as
latency-associated peptide or LAP, m 5 80 kDa), thus forming
an inactive, latent precursor or small latent complex. In order
to interact with specific cell surface serine/threonine kinase
receptors, TGF-b must dissociate from LAP, a process known
as TGF-b activation. Most TGF-b produced by cultured cells
and found in tissues is latent, suggesting that the activation
process is a key regulatory step in modulating TGF-b activity.
In most cell types and tissues, the small latent complex is
disulfide-linked during secretion to a 160–240-kDa glycopro-
tein called the latent TGF-b binding protein (LTBP). This com-
plex is known as the large latent complex. Three LTBP family
members have been described, LTBP-1, LTBP-2, and LTBP-3,
which have been cloned respectively from human and rat (5, 6),
human and bovine (7, 8), and mouse (9). All three proteins can
associate with TGF-b, but differ in their tissue distribution.
The first member to be identified, LTBP-1, was shown to be
important for assembly and secretion of small latent TGF-b in
human erythroleukemic cells (10). After secretion, LTBP-1 can
also mediate the association of the latent TGF-b complex to the
extracellular matrix (11). Alternative splicing of LTBP-1
pre-mRNA results in two forms of the protein, LTBP-1S and
LTBP-1L (12). LTBP-1L includes LTBP-1S plus an N-terminal
extension that confers higher affinity for the extracellular ma-
trix. The large latent complex formed by the association of
LTBP and small latent TGF-b is released in vitro from the
extracellular matrix upon treatment with proteases, such as
the serine proteases plasmin, mast cell chymase, and leukocyte
elastase, through partial cleavage of LTBP-1 (11, 13). Although
the release of the large latent complex from the extracellular
matrix mediated by cells has not been reported, this step is
assumed to play a role in latent TGF-b activation by allowing
interaction of the complex with the cell surface (14). Large
latent complex activation in cocultures of endothelial and
smooth muscle cells or in lipopolysaccharide-activated perito-
neal macrophages is inhibited by an excess of LTBP-1 or by
anti-LTBP-1 antibodies, suggesting a direct role for LTBP-1 in
this process (14, 15).
LTBP primary structure displays multiple tandem calcium
binding EGF-like repeats and characteristic eight-cysteine re-
peats, also called “LTBP-like” repeats. It has been recently
shown that LTBP-1 is a component of microfibrils in osteoblast
extracellular matrix, independent of its association with latent
TGF-b (16). Indeed, LTBPs share extensive structural homol-
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ogy with the extracellular matrix proteins fibrillin-1 and -2
found in the elastic fibers (17–19). This homology includes
multiple EGF-like domains and eight-cysteine repeats, which
are unique to LTBP and fibrillins. However, small latent
TGF-b was not shown to form a complex with fibrillins, raising
the question of the specificity of LTBP interaction with the
small latent complex.
To identify LTBP domains involved in the association with
latent TGF-b, we have designed deletion mutants of human
LTBP-1S and coexpressed them with human latent TGF-b1 in
insect Sf9 cells using recombinant baculoviruses, a system
suitable for observing the formation of the large latent complex.
Our results show that the third eight-cysteine repeat is neces-
sary and sufficient for association to the TGF-b1 precursor.
Mass spectrometry analysis of recombinant eight-cysteine re-
peat-3 shows that, when produced in Sf9 cells, this domain
contains no post-translational modification other than an N-
linked hybrid oligosaccharide.
MATERIALS AND METHODS
Tissue Culture —Sf9 cells were maintained in Hink’s TNM-FH sup-
plemented Grace’s medium (JRH Biosciences) containing 10% fetal calf
serum (Biomed), 0.1% Pluronic (Life Technologies, Inc.), 292 mg/ml
glutamine, 100 units/ml penicillin G, and 100 mg/ml streptomycin.
Baculovirus Transfer Vectors—The dual promoter transfer vector
pAcUW51 (Pharmingen), which bears the polyhedrin promoter and the
p10 promoter, was used to generate recombinant viruses encoding both
TGF-b1 and constructs derived from LTBP-1S. To achieve secretion of
LTBP-1S mutants deleted at the N terminus, a modified version of
pAcUW51, named pAcUGP, was constructed by substituting the XbaI-
BamHI fragment of pAcUW51, which contains the polyhedrin pro-
moter, with the EcoRV-BglII fragment of pAcGP67-A (Pharmingen), in
which the polyhedrin promoter is followed by the baculoviral protein
GP67 signal sequence and a polylinker. To produce secreted peptide
tagged with a six-histidine motif, a cassette encoding six histidines was
retrieved from vector pAcSG-His-NT C (Pharmingen) and subcloned
into pAcGP67 downstream of the GP67 signal sequence, which resulted
in vector pAcGP67-His.
Coexpression of LTBP-1S Mutants and Small Latent TGF-b1 in Sf9
Cells Using Recombinant Baculovirus—All the following constructs
were checked by automated sequencing. The fragment 68-4543 (DraI-
DraI) of the human LTBP-1S cDNA (clone BPA13, kindly provided by
Dr. Kohei Miyazono) (5), which contains the entire coding sequence,
was subcloned into pAcUW51 downstream of the polyhedrin promoter.
LTBP-1S mutants were derived from the BPA13 DraI-DraI fragment
and placed under the control of the polyhedrin promoter in pAcUW51 or
pAcUGP. All subsequent numbering refers to LTBP-1S coding se-
quence. DC1180 and DC1014 were obtained by introduction of stop
codons after the respective restriction sites Bst1107 I (position 3536)
andDpnI (position 3037). DN273 and DN441 were obtained by digestion
of BPA13 with HpaI and DraI, and ScaI and DraI respectively, and
insertion of these fragments into pAcUGP in frame with GP67 signal
sequence. Deletion of fragment 3539–3782 in the LTBP-1S coding se-
quence using flanking restriction sites Bst1107I and NaeI resulted in
mutant DCR4. To construct DCR3, the region 3264–4194 was amplified
by PCR using Taq polymerase (Boehringer Mannheim) and BPA13 as a
template with primers AATCTCGCGATGAAGCTGGTGGTGAGAAC
and GATTCTGTTTCACTCCAGGTC. The NruI site introduced in the
forward primer was used to fuse this fragment to the 39-end of LTBP-1S
cDNA digested with BsaBI (position 3031). The same fragment was also
retrieved by PCR using GCTCTAGATGAAGCTGGTGGTGAGAAC as a
forward primer and subcloned into pAcUGP in frame with GP67 signal
sequence to generate DN1088. The region 3028–3271, which encodes
the eight-cysteine repeat-3, was amplified by PCR with primers AAG-
GCCTGTAGATGTAGATCAACCCAAAG and GCTCTAGACAGCT-
TCAGAAGATGATTCTC, which adds a stop codon (TAG) at the 39-end.
Fusion of this PCR product to the GP67 signal sequence in pAcUGP
using the StuI site introduced in the forward primer resulted in con-
struct CR3. Also, ligation of this fragment to DN441 using BsaBI led to
mutants DN441CR3. Last, DN1009 was obtained by fusing construct
CR3 to the 39-end of LTBP-1S cDNA through the unique AlwNI site.
The sequence encoding human TGF-b1 was excised from the vector
pRK5-b1E (a gift from Dr. Rik Derynck) (20) with EcoRI and BglII and
placed under the control of the p10 promoter in pAcUW51 and pAcUGP
in addition to LTBP-1S wild-type or truncated forms. LTBP-1S and
TGF-b1 cDNAs were also subcloned individually into pVL1392 (Pharm-
ingen) for separate expression. To generate HisCR3, the PCR fragment
encoding the third eight-cysteine repeat (see above) was introduced into
pAcGP67-His.
All constructs were used to generate recombinant viruses with lin-
earized AcNPV DNA using the BaculoGold transfection kit (Pharmin-
gen) according to the manufacturer. For protein expression, Sf9 cells
were infected with the appropriate virus, medium was changed 4 h
post-infection for serum-free 401 medium (JRH Biosciences), and con-
ditioned media were harvested 72 h post-infection for analysis. In the
case of HisCR3, coexpression with small latent TGF-b1 was achieved by
coinfecting Sf9 cells with the recombinant viruses encoding HisCR3 and
small latent TGF-b1.
Western Blot Analysis of LTBP-1S Mutants with Small Latent TGF-
b1—LTBP-1S was detected with the polyclonal rabbit sera Ab 39 ob-
tained using LTBP-1 purified from platelets as immunogen (10). A
monoclonal antibody directed against recombinant human b1-LAP from
Chinese hamster ovary cells (mAb VB3A9) was used to reveal TGF-b1
precursor. Complexes between the small latent TGF-b1 and LTBP-1S
mutants in Sf9 cell conditioned media were immunodetected on West-
ern blot using Ab 39 (1/5,000) or mAb VB3A9 (0.6 mg/ml) and the
appropriate secondary antibody conjugated to horseradish peroxidase
(Amersham Corp.). Immunoreactive bands were revealed by processing
for chemiluminescence with the Boehringer Mannheim chemilumines-
cence kit according to the manufacturer’s instructions.
The complex of histidine-tagged peptide HisCR3 with small latent
TGF-b1 was isolated using TALON chelating resin, as described below
for the purification of recombinant peptide HisCR3, and blotted after
SDS-PAGE with mAb VB3A9.
Assay for TGF-b Activity—Conditioned media were assayed for
TGF-b activity on mink lung epithelial cells stably transfected with the
firefly luciferase reporter gene under the control of the plasminogen
activator inhibitor-1 promoter, a TGF-b responsive promoter, as de-
scribed previously (21).
Purification of Recombinant Peptide HisCR3—Sf9 cells (2 3 107
cells/15-cm dish) were infected with the recombinant baculovirus en-
coding the peptide HisCR3. Medium was changed to 401 serum-free
medium 4 h post-infection. At day 3 post-infection, conditioned medium
was harvested and dialyzed against 40 volumes of 150 mM NaCl, 20 mM
Tris, pH 7.4 (25 °C) for 24 h at 4 °C. Two ml of TALON metal-chelating
resin slurry (Clontech) were added to 50 ml of dialyzed conditioned
medium and incubated at room temperature for 1 h on a rotating
shaker. After three washes with 20 ml of dialysis buffer (one brief, 2 3
10 min), the resin was poured in a column, and the peptide was eluted
with 100 mM imidazole in dialysis buffer. Deglycosylation was per-
formed by incubating 3 mg of peptide HisCR3 with 0.5 unit of N-
glycosidase F (Boehringer Mannheim) in 10 mM phosphate buffer, pH
7.4, for 16 h at 37 °C.
Matrix-assisted Laser Desorption Mass Spectrometry—Protein and
peptide samples were prepared for matrix-assisted laser desorption/
ionization mass spectrometry using the dried droplet method (22). The
matrix used was a-cyano-4-hydroxycinnamic acid (Sigma), which was
purified by recrystallization. To produce the dried droplets, a saturated
solution of matrix was prepared in 2:1 aqueous 0.1% trifluoroacetic
acid:acetonitrile at room temperature. The sample was added to this
solution so that the final sample concentration was 1–10 mM. One-half
microliter of the solution was placed on the mass spectrometer’s probe
and allowed to dry. The sample was then analyzed.
RESULTS AND DISCUSSION
Recombinant baculoviruses encoding either human LTBP-1S
or human small latent TGF-b1 were generated for expression
in insect cells (Sf9). Sf9 cells infected with the virus encoding
LTBP-1S secreted a homogenous product with an estimated
molecular mass of 195 kDa under nonreducing conditions as
revealed by immunoblotting of the conditioned medium (Fig. 1,
lane 1). Under reducing conditions, the protein migrated at the
same position as the 205-kDa marker (not shown) as reported
for LTBP-1S from human foreskin fibroblasts (5). Sf9-produced
LTBP-1S bound to concanavalin A-Sepharose with high affin-
ity, indicating that it was glycosylated (not shown).
Analysis of the conditioned medium of cells infected with the
virus encoding small latent TGF-b1 using an anti-b1-LAP
monoclonal antibody revealed two major bands of 80 and 105
kDa under nonreducing conditions (Fig. 1, lane 3), correspond-
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ing to LAP dimer and unprocessed TGF-b1 precursor. Minor
bands, which might correspond to different glycosylation iso-
forms, were also detected. Two bands of 40 and 53 kDa were
seen after reduction of the samples (not shown). These bands
correspond to the molecular weights of LAP monomer and
uncleaved LAP-TGF-b1 monomer respectively, suggesting that
the cleavage of the pro-TGF-b1 into LAP and mature TGF-b1
was incomplete in Sf9 cells. Similar observations were previ-
ously described using mammalian cells overexpressing latent
TGF-b1 (4). Monomeric pro-TGF-b1 was detectable in Sf9 cell-
conditioned medium, probably as a result of high expression
level (not shown). In vitro activation of latent TGF-b1 by heat-
ing of the conditioned medium at 80 °C for 10 min yielded
10–20 ng/ml active TGF-b1, indicating that functional, mature
TGF-b1 was produced. Only 1–2% of the mature TGF-b1 was
present in the medium as an active form as measured without
prior heat activation.
Using a dual promoter transfer vector, we generated a re-
combinant baculovirus encoding both LTBP-1S and latent
TGF-b1 to observe the formation of large latent TGF-b1 com-
plex. When insect cells were infected with this virus, a high
molecular mass complex (estimated molecular mass 260–290
kDa) was detected with both anti-LTBP-1 and anti-b1-LAP
antibodies by Western blotting under nonreducing conditions,
indicating that Sf9 cells assembled the large latent complex
(Fig. 1, lanes 2 and 4). LTBP-1S and latent TGF-b1 were also
detected as free forms. The high molecular mass complex often
appeared as two bands, consistent with the inclusion of both
processed and unprocessed pro-TGF-b1 in the complex. Secre-
tion of the complex was efficient as more than 90% of the
immunoreactive material was recovered in the extracellular
medium. In contrast to what was reported previously in human
erythroleukemia cells (10), coexpression of latent TGF-b1 with
LTBP-1 did not change significantly the rate of latent TGF-b1
secretion (not shown).
The baculovirus expression system was next used to identify
the region of LTBP-1S responsible for its disulfide bonding to
LAP. Each LAP monomer has three cysteines. Two of these are
involved in interchain disulfide bonds in LAP dimer, whereas
the third (Cys33) is available for bonding with LTBP-1 (23).
LTBP-1S contains 139 cysteines, 10% of the total number of
amino acids (5). Each EGF-like repeat has six cysteines, which
form three intramolecular disulfide bridges and are unlikely to
be engaged in an intermolecular bond with LAP. The remain-
ing cysteines in LTBP-1S are located in the N-terminal region
at positions 35, 39, 44, 48, and 298, and in the four eight-
cysteine domains.
To determine the region containing the interchain disulfide
bonds, deletion mutants of LTBP-1S were constructed (Fig. 2)
and coexpressed with latent TGF-b1 in Sf9 cells as described
for the wild-type protein. For each mutant, the conditioned
medium was immunoblotted with anti-LTBP 1 (Fig. 3A, lanes
1–9) and anti-b1-LAP (Fig. 3A, lanes 10–21) antibodies. Dele-
tion of the N-terminal region including the eight-cysteine re-
peat-1 and -2 did not prevent the formation of a complex with
latent TGF-b (mutants DN293, lanes 3 and 12, and DN441,
lanes 4 and 13). A mutant LTBP-1S missing the C-terminal
sequence including the eight-cysteine repeat-4 (mutant
DC1180, lanes 5 and 14) still associated covalently with latent
TGF-b1. However, when the C-terminal deletion was extended
to include the eight-cysteine repeat-3 (mutant DC1014, lanes 6
and 15), no high molecular weight complex was detected, sug-
gesting that the eight-cysteine repeat-3 was involved in bond-
ing to LAP. To further assess this hypothesis, cDNAs encoding
LTBP-1S mutants lacking either the eight-cysteine repeat-3
alone (DCR3) or the eight-cysteine repeat-4 alone (DCR4) were
constructed. When expressed in Sf9 cells, DCR4 formed a com-
plex with latent TGF-b1 (lanes 8 and 17), whereas DCR3 did
not (lanes 7 and 16). Conversely, a mutant deleted at the N and
the C termini (DN441CR3), in which all of the eight-cysteine
repeats except the eight-cysteine repeat-3 were omitted, asso-
ciated with latent TGF-b1 (lanes 9 and 18). Formation of a
complex with latent TGF-b1 was also observed when the C-
terminal portion of LTBP-1 was expressed, provided that the
sequence included the eight-cysteine repeat-3 (mutants
DN1009 and DN1088, lanes 19 and 20). The complex of small
latent TGF-b1 with LTBP-1 mutant DN1009 was detected with
anti-b1-LAP mAb VB3A9, but not with anti-LTBP-1 Ab 39 (not
shown). Finally, the eight-cysteine repeat-3 (CR3) was ex-
pressed together with small latent TGF-b1. Western blot anal-
ysis of the conditioned medium with anti-b1-LAP antibodies
revealed a complex migrating above latent TGF-b1 (lane 21).
When the eight-cysteine repeat-3 was fused to a six-histidine
tag (HisCR3) and coexpressed with small latent TGF-b1, the
complex (but not the small latent TGF-b1 alone) was retained
on a metal-chelating resin (Fig. 3B), confirming that the eight-
cysteine repeat-3 associated covalently with latent TGF-b1.
Mixing of cells expressing separately the HisCR3 peptide and
small latent TGF-b1 did not result in complex formation, indi-
cating that coexpression of the two molecules was necessary for
their association (not shown). Bonding of small latent TGF-b1
to the eight-cysteine repeat-3 appeared to be more efficient
than to full-length LTBP-1S (Fig. 3A); the same phenomenon
was also reproducibly observed with constructs DN293 and
DN441, which may be explained by higher expression levels of
these mutants as compared to wild-type LTBP-1S. These re-
sults show that the eight-cysteine repeat-3 is necessary and
sufficient for association of LTBP-1 to latent TGF-b1.
To further characterize the eight-cysteine repeat-3, Sf9 cells
were infected with the baculovirus encoding the eight-cysteine
repeat-3 fused to a six-histidine motif HisCR3 (see sequence in
Fig. 4A) and the recombinant peptide was purified by metal-
affinity chromatography. The purified peptide, whose predicted
molecular mass is 12,237 Da after processing of the signal-
sequence, migrated on SDS-PAGE with an estimated molecu-
lar mass of 20–21 kDa (Fig. 4B). As the eight-cysteine repeat-3
in LTBP-1S contains Asn1039 (Asn101 in HisCR3, Fig. 4A) in the
FIG. 1. Production of small latent TGF-b1, LTBP-1S, and large
latent complex by Sf9 cells. Sf9 cells were infected with recombinant
baculovirus encoding small latent TGF-b1 (SL TGF-b1), LTBP-1S, or
both. At day 3 post-infection, conditioned media were analyzed after
SDS-PAGE (7% gel, nonreducing conditions) by immunoblotting with
anti-LTBP-1 serum Ab 39 (lanes 1 and 2) or with anti-b1-LAP mono-
clonal antibody VB3A9 (lanes 3 and 4).
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proper context for N-glycosylation (N/X/S or T), we treated the
purified peptide with N-glycosidase F to determine whether
N-glycosylation accounted for the distortion in electrophoretic
mobility. However, this treatment resulted in a slightly slower
migration on SDS-PAGE with an estimated molecular mass of
21–22 kDa (Fig. 4B). To assess further the presence of post-
translational modifications, the peptide was subjected to mass
spectrometry. Analysis of the native peptide (Fig. 5A) revealed
two major molecular species with molecular masses of 13,266
Da (peak A) and 13,345 Da (peak B), respectively. Treatment
with N-glycosidase F decreased the mass of these molecular
ions, confirming that the peptide is N-glycosylated (Fig. 5B).
This spectrum showed two peaks, one at 12,230 Da (peak A1),
which is equal to the predicted molecular mass of the peptide,
and one at 12,309 Da (peak B1), indicating the presence of a
79-Da post-translational modification resistant to N-glycosi-
dase F. The 1,036-Da difference between peaks A and A1 or
peaks B and B1 is compatible with the linkage of a truncated
high mannose oligosaccharide Man3GlcNAc2 linked to a fucose
residue. To enhance visualization of the glycosylation pattern,
the glycosylated peptide was digested with trypsin and ana-
lyzed by mass spectrometry (Fig. 5C). Peaks I (9,011 Da) and II
(9,198 Da) correspond to the nonglycosylated forms of frag-
ments 65–138 and 65–140, respectively, whereas the same
fragments with an additional fucosylated Man3GlcNAc2 are
found in peaks IV and VI. The nonfucosylated forms of the
glycosylated fragments are also detected (peaks III and V).
However, the 79-Da modification was not detected on these
peptides. Analysis of the proteolytic fragments obtained with
FIG. 2. Peptides encoded by LTBP-1S constructs. Cysteines in
LTBP-1S are located in EGF-like domains, eight-cysteine repeats, and
at positions numbered above the schematic of the wild-type protein. The
LTBP-1S domains encoded by these constructs are the following: wild-
type, 1–1394; DN293, 294-1394; DN441, 442-1394; DC1180, 1–1179;
DC1014, 1–1013; DCR3, deletion of 1014–1088; DCR4, deletion of 1180–
1258; DN441CR3, 442-1090; DN1009, 1010–1394; DN1088, 1089–1394;
CR3, 1010–1090; HisCR3, 1012–1090.
FIG. 3. Mapping of LTBP-1S domain mediating bonding with small latent complex. Conditioned media of Sf9 cells infected with
recombinant baculovirus bearing both small latent TGF-b1 (SL TGF-b1) cDNA and one of LTBP-1S cDNA mutants were subjected to SDS-PAGE
(7% gel) under nonreducing conditions and immunoblotted with anti-LTBP-1 serum Ab 39 (lanes 1–9) and anti-b1-LAP mAb VB3A9 (lanes 10–21).
In B, Sf9 cells were coinfected with two recombinant baculoviruses, one encoding small latent TGF-b1 and the other histidine-tagged peptide
HisCR3; the presence of a complex between the two proteins in the conditioned medium was assessed by precipitation with metal-chelating resin
followed by SDS-PAGE and Western blot analysis with mAb VB3A9. The higher immunoreactive band might correspond to the association of the
HisCR3 peptide with the small latent complex in a 2:1 ratio, as a result of artifactual disulfide bond exchange on the surface of the chelating resin.
FIG. 4. Sequence and SDS-PAGE analysis of peptide HisCR3. A,
the amino acid sequence of peptide HisCR3 comprises baculoviral pro-
tein GP67 signal peptide (crossed out), a six-histidine motif (bold), a
linker with a thrombin cut site (dashed line) and LTBP-1S domain
1012–1090 (plain characters), which includes a putative N-glycosyla-
tion site (overlined). B, HisCR3 peptide purified by immobilized metal
affinity chromatography was subjected to SDS-PAGE on a 15% gel
(nonreducing conditions) before and after treatment with N-glycosidase
F. N-Glycosidase F appears as a faint band (m 5 32.2 kDa).
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trypsin or V8 protease demonstrated that the 79-Da shift in
peak B1 was due to an undetermined post-translational mod-
ification located in the linker of the histidine tag outside of the
eight-cysteine repeat (not shown). Therefore,N-glycosylation is
the only post-translational modification of the eight-cysteine
repeat-3 produced in Sf9 cells.
In order to assess the presence of reduced cysteines in the
HisCR3 peptide, alkylation under denaturing conditions was
performed using vinyl pyridine and the peptide was analyzed
by mass spectrometry. No mass shift was observed, suggesting
that the eight cysteines were involved in intramolecular bonds.
The experiments presented here demonstrate that LTBP-1S
associates covalently to TGF-b1 through the third eight-cys-
teine repeat. During the preparation of this manuscript, a
study reaching a similar conclusion about the role of the eight-
cysteine repeat-3 in the covalent association of LTBP-1S to
TGF-b1 in mammalian cells was published by Saharinen et al.
(24). No other function has been described for this type of
repeat, which is found in LTBPs and fibrillin-1 and -2. How-
ever, fibrillins do not covalently bind TGF-b, and within
LTBP-1, association with TGF-b seems characteristic of the
third eight-cysteine repeat. Mass spectrometry analysis of re-
combinant LTBP-1 eight-cysteine repeat-3 produced in insect
cells showed that it is N-glycosylated. The N-linked glycosidic
residue in these cells appears to be mainly a truncated hybrid
sugar (Man3GlcNAc2) with occasional addition of a fucose res-
idue. The Man3GlcNAc2 pentasaccharide has been described as
a common N-linked oligosaccharide in lepidopteran cells (25,
26), but is rarely found in proteins synthesized by vertebrate
cells. The presence in lepidopteran cells of a fucosyltransferase
that can add a fucose residue to the asparagine-linked GlcNAc
residue also has been established (27). Among the three LT-
BPs, the third eight-cysteine repeat is the only one to contain
an N-glycosylation site. Glycosylation could change the confor-
mation of this domain and favor its association with LAP.
However, fibrillin-1 and -2 contain several eight-cysteine do-
mains with putative N-glycosylation sites and were not shown
to date to associate with small latent TGF-b, suggesting that
N-glycosylation of the eight-cysteine repeat-3 is not the sole
feature for association with small latent TGF-b. Indeed, our
results show that LTBP-1S eight-cysteine repeat-3 associates
with small latent TGF-b1 even when the N-linked glycosidic
residue is a trimmed pentasaccharide. Accordingly, as reported
by Saharinen et al. (24), point-mutagenesis of Asn1039 in the
eight-cysteine repeat-3 to Ala does not prevent the association
process in mammalian cells.
Mass spectrometry characterization of the eight-cysteine re-
peat-3 shows unambiguously that no other post-translational
modification of this domain is needed for bonding to TGF-b1.
This conclusion is in contrast with that of Saharinen et al. (24),
who speculated that other post-translational modifications,
such as O-glycosylation, might play a role in the association
process. This was based on their observation of the anomalous
electrophoretic mobility of N-glycosidase F treated peptides
that contained the eight-cysteine repeat-3, which seemed to
indicate that N-glycosylation was not the only post-transla-
tional modification. From the data presented here, the retarded
migration of the eight-cysteine repeat-3 on SDS-PAGE appears
to be an intrinsic property of this peptide, which may be related
to its conformation. Because insect cells are unable to perform
some of the post-translational modifications found in mam-
mals, we cannot rule out the possibility that additional post-
translational modifications of this domain occur in mammalian
cells. However, such modifications are not necessary for the
ability of the eight-cysteine repeat-3 to associate with TGF-b.
The absence of free cysteines in the recombinant HisCR3
peptide suggests that the eight-cysteine repeat-3 adopts an
alternative structure for intermolecular bonding with the small
latent complex. Remarkably, this domain binds to LAP out of
the context of LTBP-1, suggesting the specific recognition of the
small latent complex by the eight-cysteine repeat-3. This rec-
ognition mechanism may be essential for the formation of the
large latent complex. For example, an initial noncovalent in-
teraction of the eight-cysteine repeat-3 with small latent
TGF-b could induce a conformational change in the eight-
cysteine repeat-3 that would, in turn, favor disulfide bond
exchange. Alternatively, this recognition step might occur be-
tween partially folded intermediates of LTBP and the TGF-b
precursor at an early step during secretion, yielding formation
of intermolecular disulfide bonds. The idea of an interaction
between LTBP and the TGF-b precursor early in the secretion
pathway is supported by the role of LTBP in the assembly and
the processing of small latent TGF-b (10).
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